EUCTR2008-000256-26-GB进行中（未招募）不适用
An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonß-1a (IFNß-1a, Rebif®) therapy in the induction of tolerance to IFNß in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNß-1a (Rebif® or Avonex®) - Tolerance induction with intravenous IFNß-1a
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Confirmed diagnosis of MS according to the McDonald criteria
- •2.Current treatment with Rebif® (22 or 44) s.c. TIW or Avonex® i.m. once per week for at least 12 months
- •3.At least one relapse in the last 12 months
- •4.Two consecutive positive NAb titers of =20NU at least 4 weeks apart
- •5.Age over 18 years and less than 65 years
- •6.EDSS not to exceed 6.5
- •7.Women of childbearing potential must agree to practice adequate contraception
- •8.Must give written informed consent and authorize the release and use of protected health information
- •9.Able and willing to undergo blood sampling at regular intervals as defined by the protocol
- •10.Able to comply with study requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Treatment with other immunosuppressive, immunomodulatory, or experimental treatments within the last 6 months of enrollment in the study, but excluding pulsed intravenous or oral steroids for treatment of MS relapse
- •2.History of WHO grade 3 or 4 liver toxicity with IFNß-1a
- •3.Patients presenting a severe or unstable disorder: poorly controlled diabetes, arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, clinically significant laboratory abnormality, or any medical condition which, in the opinion of the chief investigator, would pose additional risk in administering IFNß-1 to the patient
- •4.Presence of chronic or recurrent infection or human immunodeficiency virus
- •5.Exposure to any other investigational drug within 30 days of enrollment in the study
- •6.History of malignancy unless an exception is granted by the Chief Investigator
- •7.History of drug or alcohol abuse within 6 months prior to enrollment into the study
- •8.Pregnancy or breast feeding
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II pilot study to evaluate safety and efficacy of the addition of vismodegib to standard neoadjuvant chemotherapy in triple negative breast cancer patients.MedDRA version: 17.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2014-001287-35-ESClínica Universidad de Navarra/Universidad de Navarra40
未知
1 期
A Phase 1, 2, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinomanresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaJPRN-jRCT2080221951AstraZeneca
进行中（未招募）
不适用
A phase I/II multicentre study to evaluate the safety and efficacy of rituximab (monoclonal antibody anti-CD20) for prevention and/or therapy of EBV-disease. - NDOT AVAILABLEMedDRA version: 9.1Level: LLTClassification code 10015108Term: Epstein-Barr virus infectionEUCTR2007-000468-26-ITOSPEDALE POLICLINICO S. MATTEO
已完成
不适用
A prospective trial investigating the safety and efficacy of dose-escalated radiotherapy for men with prostate cancer following insertion of a gel spacer between the prostate and rectumProstate CancerACTRN12621000056897Epworth HealthCare71
已完成
1 期
A Study of Lazertinib as Monotherapy or in Combination with Amivantamab in Participants with Advanced Non-small Cell Lung CancerJPRN-jRCT2080224850Janssen Pharmaceutical K.K.520